Ethyreal Bio Overview
- Year Founded
-
2024
- Status
-
Private
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$60M
- Investors
-
5
Ethyreal Bio General Information
Description
Developer of a biotechnology research platform intended for precision targeting of the causal disease process underlying both conditions. The company's platform offers a monoclonal antibody designed to block autoantibody-mediated activation of the thyroid-stimulating hormone receptor, the shared pathogenic driver of Graves' disease and thyroid eye disease, enabling patients to get the required medicine for their conditions and get treated in the right way.
Contact Information
Website
www.ethyrealbio.comCorporate Office
- 700 Technology Square
- Floor 3
- Cambridge, MA 02139
- United States
Corporate Office
- 700 Technology Square
- Floor 3
- Cambridge, MA 02139
- United States
Ethyreal Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 10-Jun-2026 | $60M | Completed | Pre-Clinical Trials | ||
| 2. Early Stage VC (Series A) | Completed | Pre-Clinical Trials | ||||
| 1. Seed Round | $3.3M | $3.3M | Completed | Pre-Clinical Trials |
Ethyreal Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed-NV | 4,035,797 | $0.000010 | $0 | $0 | 1x | $0 | 4.97% | |
| Seed | 3,300,000 | $0.000010 | $1 | $1 | 1x | $1 | 4.06% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Ethyreal Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ethyreal Bio Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atlas Venture | Venture Capital | Minority | ||
| Avoro Capital | Venture Capital | Minority | ||
| Checkpoint Capital | Hedge Fund | Minority | ||
| Medicxi Ventures (UK) | Venture Capital | Minority | ||
| Nandi Life Sciences | Family Office | Minority |
Ethyreal Bio FAQs
-
When was Ethyreal Bio founded?
Ethyreal Bio was founded in 2024.
-
Where is Ethyreal Bio headquartered?
Ethyreal Bio is headquartered in Cambridge, MA.
-
What industry is Ethyreal Bio in?
Ethyreal Bio’s primary industry is Biotechnology.
-
Is Ethyreal Bio a private or public company?
Ethyreal Bio is a Private company.
-
What is the current valuation of Ethyreal Bio?
The current valuation of Ethyreal Bio is .
-
What is Ethyreal Bio’s current revenue?
The current revenue for Ethyreal Bio is .
-
How much funding has Ethyreal Bio raised over time?
Ethyreal Bio has raised $104M.
-
Who are Ethyreal Bio’s investors?
Atlas Venture, Avoro Capital, Checkpoint Capital, Medicxi Ventures (UK), and Nandi Life Sciences have invested in Ethyreal Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
